Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of AZD6234 in adults with obesity or overweight with weight-related comorbidity without type 2 diabetes mellitus
2025-523379-41-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing AZD6234 with Placebo to match AZD6234 (2 arms). Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment. Planned start Oct 2026; status: authorised.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-523379-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523379-41-00.